|Articles|December 16, 2009

Sanofi Gets a Bad Batch of H1N1 Vaccines

Sanofi-Aventis is recalling hundreds of thousands of doses of the childrens' version of its H1N1 vaccine. Conspiracy theorists are going to have a field day.

Looks like the conspiracy theorists boycotting the H1N1 vaccine because it was approved too quickly may have some more ammo. The Wall Street Journal, on Wednesday, reported that Sanofi-Aventis is recalling close to 800,000 does of the childrens’ version of the H1N1 vaccine due to potency problems.

According to the Center for Disease Control and Prevention (CDC), the pre-filled syringes were voluntarily recalled for non-safety–related reasons. Sanofi-Aventis discovered that a batch of the vaccine wasn’t as strong as it should have been, and notified the CDC and FDA that it will recall four lots of doses.

CDC informed the public that there are no safety concerns regarding these lots, and that the potency is only “slightly below the specified range.”

The following lots are affected:

  • 0.25 ml pre-filled syringes, 10-packs (NDC # 49281-650-25, sometimes coded as 49281-0650-25): UT023DA, UT028DA, UT028CB

  • 0.25 ml pre-filled syringes, 25-packs (NDC # 49281-650-70, sometimes coded as 49281-0650-70): UT030CA

No H1N1 vaccines manufactured by other companies are being recalled at this time.

In a press statement, Sanofi stated that "no action is needed other than to return unused doses. The FDA and the CDC recommend not repeating the dose for children who received vaccine from these lots because the drop in antigen content is unlikely to result in a clinically significant reduction in immune response. The CDC has stated that parents of children who received vaccine from the recalled lots do not need to take any action other than to complete the two-dose immunization series if not already completed."


Related to this article

How QMM Can Help the C-Suite See a  $100 Million Problem Early
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.